Historical salary details - Dr. Ali Behbahani, M.B.A.,M.D., Independent Director, Korro Bio Inc.
Dr. Ali Behbahani, M.B.A.,M.D. is the Independent Director of Korro Bio Inc.. They also hold 4 other positions in CVRx Inc, CRISPR Therapeutics AG, Arcellx Inc and Black Diamond Therapeutics Inc.
Dr. Ali Behbahani, M.B.A.,M.D.
Independent Director
-
Gross Remuneration
-
Current Company
Korro Bio Inc.
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Korro Bio Inc. | Independent Director | - | - |
| 2024 | CVRx Inc | Independent Director | - | - |
| 2024 | CRISPR Therapeutics AG | Independent Director | - | - |
| 2024 | Arcellx Inc | Independent Director | - | - |
| 2024 | Black Diamond Therapeutics Inc | Independent Director | - | - |
| 2023 | CRISPR Therapeutics AG | Independent Director | 545.1 K | -10.8 % |
| 2023 | Arcellx Inc | Independent Director | 355.2 K | 773.4 % |
| 2023 | Nkarta Inc | Chairman of the Board | 166.8 K | - |
| 2023 | Monte Rosa Therapeutics Inc | Independent Director | 140.9 K | 14.6 % |
| 2023 | Adaptimmune Therapeutics Plc - ADR | - | 111.5 K | -27.4 % |
| 2023 | Black Diamond Therapeutics Inc | Independent Director | 68.1 K | -3.1 % |
| 2023 | Korro Bio Inc. | Independent Director | - | - |
| 2023 | CVRx Inc | Independent Director | - | - |
| 2022 | CRISPR Therapeutics AG | Independent Director | 610.9 K | -24.5 % |
| 2022 | Minerva Surgical Inc | Independent Director | 180.0 K | 1442.1 % |
| 2022 | CVRx Inc | Independent Director | 160.0 K | 72.8 % |
| 2022 | Adaptimmune Therapeutics Plc - ADR | Independent Director | 153.6 K | -36.9 % |
| 2022 | Monte Rosa Therapeutics Inc | Independent Director | 122.9 K | -80.1 % |
| 2022 | Black Diamond Therapeutics Inc | Independent Director | 70.3 K | -59.3 % |
| 2022 | Arcellx Inc | Independent Director | 40.7 K | - |
| 2022 | Korro Bio Inc. | Independent Director | - | - |
| 2022 | Nkarta Inc | Chairman of the Board | - | - |
| 2021 | CRISPR Therapeutics AG | Independent Director | 808.8 K | 36.6 % |
| 2021 | Monte Rosa Therapeutics Inc | Independent Director | 616.6 K | - |
| 2021 | Nkarta Inc | Chairman of the Board | 350.5 K | 120.7 % |
| 2021 | Adaptimmune Therapeutics Plc - ADR | Independent Director | 243.5 K | 6.1 % |
| 2021 | Black Diamond Therapeutics Inc | Independent Director | 172.7 K | 229.0 % |
| 2021 | CVRx Inc | Independent Director | 92.6 K | - |
| 2021 | Minerva Surgical Inc | Independent Director | 11.7 K | - |
| 2021 | Arcellx Inc | Independent Director | - | - |
| 2020 | CRISPR Therapeutics AG | Independent Director | 592.0 K | 32.0 % |
| 2020 | Adaptimmune Therapeutics Plc - ADR | Independent Director | 229.6 K | 164.8 % |
| 2020 | Nkarta Inc | Chairman of the Board | 158.8 K | - |
| 2020 | Black Diamond Therapeutics Inc | Independent Director | 52.5 K | - |
| 2020 | CVRx Inc | Independent Director | - | - |
| 2020 | Minerva Surgical Inc | Independent Director | - | - |
| 2020 | Monte Rosa Therapeutics Inc | Director | - | - |
| 2019 | CRISPR Therapeutics AG | Independent Director | 448.4 K | -30.7 % |
| 2019 | Adaptimmune Therapeutics Plc - ADR | Independent Director | 86.7 K | -53.5 % |
| 2019 | Nevro Corp | - | 14.8 K | -95.7 % |
| 2019 | Black Diamond Therapeutics Inc | Independent Director | - | - |
| 2019 | Nevro Corp | Independent Director | - | - |
| 2019 | Nkarta Inc | Chairman of the Board | - | - |
| 2018 | CRISPR Therapeutics AG | Independent Director | 646.8 K | 268.6 % |
| 2018 | Nevro Corp | Independent Director | 343.9 K | 17.0 % |
| 2018 | Adaptimmune Therapeutics Plc - ADR | Independent Director | 186.3 K | 76.7 % |
| 2017 | Nevro Corp | Independent Director | 293.9 K | 105.5 % |
| 2017 | CRISPR Therapeutics AG | Independent Director | 175.5 K | -42.4 % |
| 2017 | Adaptimmune Therapeutics Plc - ADR | Independent Director | 105.5 K | -22.5 % |
| 2016 | CRISPR Therapeutics AG | Independent Director | 304.6 K | - |
| 2016 | Nevro Corp | Independent Director | 143.0 K | -0.0 % |
| 2016 | Adaptimmune Therapeutics Plc - ADR | Independent Director | 136.0 K | - |
| 2015 | Nevro Corp | Independent Director | 143.0 K | 67.1 % |
| 2015 | CRISPR Therapeutics AG | Independent Director | - | - |
| 2015 | Adaptimmune Therapeutics Plc - ADR | Independent Director | - | - |
| 2014 | Nevro Corp | Independent Director | 85.6 K | - |
| 2014 | Adaptimmune Therapeutics Plc - ADR | Independent Director | - | - |
| 2013 | Nevro Corp | Independent Director | - | - |